Study of Safety and Effectiveness of Hypofractionated Radiotherapy for Treating Localized Prostate Cancer in Men

What this Trial Is About

Researchers are evaluating the safety outcomes of hypofractionated radiotherapy in patients with localized prostate cancer. This approach delivers higher doses of radiation in a shorter time, potentially killing more tumor cells while causing fewer side effects. Although evidence supports its safety and feasibility, the optimal dose per treatment for localized prostate cancer is still being determined. Participants will receive hypofractionated radiation therapy with a total dose of 54 Gy delivered in 15 daily treatments of 3.6 Gy each over three weeks. After completing treatment, patients will be followed up monthly for the first three months and then every three months for up to five years to monitor health and treatment effects. During the study, researchers will assess side effects related to the gastrointestinal and urinary systems, as well as erectile function. They will also track progression-free survival, local control, distant metastasis, overall survival, quality of life, and physical activity over five years. Safety and patient well-being will be closely monitored throughout the trial period.

Radical Hypofractionated Radiotherapy for Localized Prostate Cancer